Cargando…

Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics

As multidrug-resistant bacteria represent a concerning burden, experts insist on the need for a dramatic rethinking on antibiotic use and development in order to avoid a post-antibiotic era. New and rapidly developable strategies for antimicrobial substances, in particular substances highly potent a...

Descripción completa

Detalles Bibliográficos
Autores principales: Umstätter, Florian, Werner, Julia, Zerlin, Leah, Mühlberg, Eric, Kleist, Christian, Klika, Karel D., Hertlein, Tobias, Beijer, Barbro, Domhan, Cornelius, Zimmermann, Stefan, Ohlsen, Knut, Haberkorn, Uwe, Mier, Walter, Uhl, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880691/
https://www.ncbi.nlm.nih.gov/pubmed/35215272
http://dx.doi.org/10.3390/ph15020159
_version_ 1784659279848931328
author Umstätter, Florian
Werner, Julia
Zerlin, Leah
Mühlberg, Eric
Kleist, Christian
Klika, Karel D.
Hertlein, Tobias
Beijer, Barbro
Domhan, Cornelius
Zimmermann, Stefan
Ohlsen, Knut
Haberkorn, Uwe
Mier, Walter
Uhl, Philipp
author_facet Umstätter, Florian
Werner, Julia
Zerlin, Leah
Mühlberg, Eric
Kleist, Christian
Klika, Karel D.
Hertlein, Tobias
Beijer, Barbro
Domhan, Cornelius
Zimmermann, Stefan
Ohlsen, Knut
Haberkorn, Uwe
Mier, Walter
Uhl, Philipp
author_sort Umstätter, Florian
collection PubMed
description As multidrug-resistant bacteria represent a concerning burden, experts insist on the need for a dramatic rethinking on antibiotic use and development in order to avoid a post-antibiotic era. New and rapidly developable strategies for antimicrobial substances, in particular substances highly potent against multidrug-resistant bacteria, are urgently required. Some of the treatment options currently available for multidrug-resistant bacteria are considerably limited by side effects and unfavorable pharmacokinetics. The glycopeptide vancomycin is considered an antibiotic of last resort. Its use is challenged by bacterial strains exhibiting various types of resistance. Therefore, in this study, highly active polycationic peptide-vancomycin conjugates with varying linker characteristics or the addition of PEG moieties were synthesized to optimize pharmacokinetics while retaining or even increasing antimicrobial activity in comparison to vancomycin. The antimicrobial activity of the novel conjugates was determined by microdilution assays on susceptible and vancomycin-resistant bacterial strains. VAN1 and VAN2, the most promising linker-modified derivatives, were further characterized in vivo with molecular imaging and biodistribution studies in rodents, showing that the linker moiety influences both antimicrobial activity and pharmacokinetics. Encouragingly, VAN2 was able to undercut the resistance breakpoint in microdilution assays on vanB and vanC vancomycin-resistant enterococci. Out of all PEGylated derivatives, VAN:PEG1 and VAN:PEG3 were able to overcome vanC resistance. Biodistribution studies of the novel derivatives revealed significant changes in pharmacokinetics when compared with vancomycin. In conclusion, linker modification of vancomycin-polycationic peptide conjugates represents a promising strategy for the modulation of pharmacokinetic behavior while providing potent antimicrobial activity.
format Online
Article
Text
id pubmed-8880691
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88806912022-02-26 Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics Umstätter, Florian Werner, Julia Zerlin, Leah Mühlberg, Eric Kleist, Christian Klika, Karel D. Hertlein, Tobias Beijer, Barbro Domhan, Cornelius Zimmermann, Stefan Ohlsen, Knut Haberkorn, Uwe Mier, Walter Uhl, Philipp Pharmaceuticals (Basel) Article As multidrug-resistant bacteria represent a concerning burden, experts insist on the need for a dramatic rethinking on antibiotic use and development in order to avoid a post-antibiotic era. New and rapidly developable strategies for antimicrobial substances, in particular substances highly potent against multidrug-resistant bacteria, are urgently required. Some of the treatment options currently available for multidrug-resistant bacteria are considerably limited by side effects and unfavorable pharmacokinetics. The glycopeptide vancomycin is considered an antibiotic of last resort. Its use is challenged by bacterial strains exhibiting various types of resistance. Therefore, in this study, highly active polycationic peptide-vancomycin conjugates with varying linker characteristics or the addition of PEG moieties were synthesized to optimize pharmacokinetics while retaining or even increasing antimicrobial activity in comparison to vancomycin. The antimicrobial activity of the novel conjugates was determined by microdilution assays on susceptible and vancomycin-resistant bacterial strains. VAN1 and VAN2, the most promising linker-modified derivatives, were further characterized in vivo with molecular imaging and biodistribution studies in rodents, showing that the linker moiety influences both antimicrobial activity and pharmacokinetics. Encouragingly, VAN2 was able to undercut the resistance breakpoint in microdilution assays on vanB and vanC vancomycin-resistant enterococci. Out of all PEGylated derivatives, VAN:PEG1 and VAN:PEG3 were able to overcome vanC resistance. Biodistribution studies of the novel derivatives revealed significant changes in pharmacokinetics when compared with vancomycin. In conclusion, linker modification of vancomycin-polycationic peptide conjugates represents a promising strategy for the modulation of pharmacokinetic behavior while providing potent antimicrobial activity. MDPI 2022-01-28 /pmc/articles/PMC8880691/ /pubmed/35215272 http://dx.doi.org/10.3390/ph15020159 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Umstätter, Florian
Werner, Julia
Zerlin, Leah
Mühlberg, Eric
Kleist, Christian
Klika, Karel D.
Hertlein, Tobias
Beijer, Barbro
Domhan, Cornelius
Zimmermann, Stefan
Ohlsen, Knut
Haberkorn, Uwe
Mier, Walter
Uhl, Philipp
Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics
title Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics
title_full Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics
title_fullStr Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics
title_full_unstemmed Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics
title_short Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics
title_sort impact of linker modification and pegylation of vancomycin conjugates on structure-activity relationships and pharmacokinetics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880691/
https://www.ncbi.nlm.nih.gov/pubmed/35215272
http://dx.doi.org/10.3390/ph15020159
work_keys_str_mv AT umstatterflorian impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics
AT wernerjulia impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics
AT zerlinleah impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics
AT muhlbergeric impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics
AT kleistchristian impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics
AT klikakareld impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics
AT hertleintobias impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics
AT beijerbarbro impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics
AT domhancornelius impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics
AT zimmermannstefan impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics
AT ohlsenknut impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics
AT haberkornuwe impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics
AT mierwalter impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics
AT uhlphilipp impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics